

## Special Issue

# Clinical Strategies to Improve Efficacy, Effectiveness, and Safety of Vaccination in Humans

### Message from the Guest Editor

I am pleased to invite you to contribute to an upcoming Special Issue, titled "Clinical Strategies to Improve Efficacy, Effectiveness, and Safety of Vaccination in Humans". Vaccination remains a cornerstone in preventing infectious diseases and is a key contributor to global health. In this context, advancing clinical strategies is crucial for enhancing the overall impact of vaccination programs. The scientific foundation of this Special Issue lies in addressing current challenges and exploring innovative approaches to optimize vaccination outcomes. Embracing a broad scope, we welcome contributions involving, but not limited to, the following:

- Participants of all ages.
- Special populations as those with comorbid conditions and immunocompromised patients.
- The use of any human vaccine platform.
- Diverse research designs, including randomized trials, nonrandomized trials, quality improvement studies, case-control studies, systematic reviews, and narrative reviews.
- Clinical vaccine research and utilization under controlled or real-world settings.

### Guest Editor

Dr. Kay Choong See

Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Hospital, Singapore 119228, Singapore

### Deadline for manuscript submissions

31 May 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/197121](https://mdpi.com/si/197121)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).